Heart Foundation's obesity-CVD guide: when GLP-1s make clinical sense

The headline writes itself: GLP-1 drugs endorsed for heart disease. But the actual story is considerably more granular than the one-liner, and the detail is what will make this useful to you.

What just happened

On 22 May 2026, at the WHO World Health Assembly in Geneva, the National Heart Foundation of Australia presented Australia’s first Clinical Consensus Statement on Obesity and Cardiovascular Disease. The statement is the result of twelve months of development, a twenty-two-expert National Taskforce, and more than 800 individual pieces of feedback during public consultation. It is the first Australian clinical document to formally recommend specific weight-loss medicines for cardiovascular risk reduction.

For the woman who has been managing her weight carefully for years while watching her blood pressure creep up and her cardiovascular risk score edge higher, who has been told losing weight would help but has never been offered a structured pharmacological pathway to get there: something shifted in Australian clinical guidance this week.

If you have established heart disease and you’re carrying weight that hasn’t shifted despite genuine effort — or if you have type 2 diabetes alongside elevated cardiovascular risk — this statement changes what conversations you can now have with your GP.

---

The both-and

The evidence base for GLP-1 therapies in established cardiovascular disease is genuinely strong. The access situation in Australia is genuinely poor. Both are true simultaneously.

What the statement actually recommends

The consensus statement organises treatment into four pillars: a heart-healthy eating pattern with reduced energy intake; regular physical activity combining moderate-to-vigorous aerobic training and resistance work; pharmacotherapy — specifically GLP-1 and GIP/GLP-1 receptor agonists — for eligible patients; and bariatric surgery for those who meet surgical criteria.

On GLP-1 therapies, the specifics matter. For people with established atherosclerotic cardiovascular disease (ASCVD) and a BMI ≥ 27 kg/m² without type 2 diabetes, the statement recommends semaglutide for weight management and cardiovascular risk reduction. The evidence anchor is the SELECT trial — covered in MJA InSight’s analysis of the statement — which demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE: heart attack, stroke, or cardiovascular death) with semaglutide 2.4 mg weekly in this population over approximately 3.3 years. Before SELECT, there was no pharmacotherapy option beyond statins and antihypertensives for adults with established CVD who had obesity but not diabetes. That gap has now been formally addressed.

For adults with type 2 diabetes and elevated cardiovascular risk, the statement endorses semaglutide, liraglutide, and tirzepatide. Semaglutide and tirzepatide have also demonstrated benefit in some types of heart failure — specifically heart failure with preserved ejection fraction, a condition that disproportionately affects women over 60 and has historically had limited treatment options.

As MJA InSight noted in its coverage, GPs are expected to be central to delivery of this framework — not merely as referrers, but as active clinicians integrating obesity management into cardiovascular care.

What the statement doesn’t resolve

According to newsGP’s coverage, access remains the structural challenge. Where GLP-1 therapies are PBS-listed at all, it is only for type 2 diabetes management — and tirzepatide (Mounjaro) is not listed even there, its sponsor having declined the terms of the March 2026 PBAC recommendation. Semaglutide for weight loss (Wegovy) is TGA-approved and commercially available, but for obesity without a concurrent diabetes diagnosis the cost is private — typically $150 to $450 per month depending on the agent and dose. That is not affordable for most Australians on a sustained basis. Semaglutide (Wegovy) carries a December 2025 PBAC recommendation for obesity with established cardiovascular disease — not yet in effect as of June 2026; no obesity listing for tirzepatide has been recommended. A clinical consensus statement changes what GPs can recommend and what conversations are now clinically sanctioned; it does not change what is affordable without subsidy. Those are different levers.

Who this is actually for

The strongest cardiovascular outcome data behind this recommendation — the SELECT trial — enrolled people with established cardiovascular disease and obesity. The evidence for GLP-1 therapies in lower-risk obesity (no established CVD, no type 2 diabetes) is less definitive, and the consensus is appropriately targeted. It is not a blanket endorsement for weight management in everyone with obesity. The recommendation is most clearly supported in those at highest cardiovascular risk — a distinction that matters for conversations in general practice.

The statement also directly addresses weight stigma — something that rarely appears in clinical guidelines but is long overdue. It asks clinicians to use weight-inclusive language and to approach obesity as a chronic, relapsing metabolic condition that warrants medical management, not moral instruction. The system has historically been better at telling people to eat less and move more than at treating the underlying biology. The statement is a formal acknowledgement that the biology is real and the treatment gap has been real.

---

2 cents

If you have established cardiovascular disease, type 2 diabetes, or significant cardiovascular risk and you’ve been managing your weight with lifestyle modifications alone — this consensus statement changes what the evidence formally supports as an additional option.

The conversation worth having with your GP: has your cardiovascular risk been formally assessed recently? If you have established ASCVD — prior myocardial infarction, angina, coronary artery disease — and a BMI ≥ 27 without type 2 diabetes, the SELECT data now positions semaglutide as an evidence-based addition to your cardiovascular risk management, not an afterthought. If you have type 2 diabetes and elevated cardiovascular risk, liraglutide and tirzepatide are also formally endorsed. Your GP can work through which, if any, of these applies to your specific picture — and what the access pathway and cost look like in practice.

If you’re otherwise metabolically well and primarily interested in weight management, this statement is specifically for high-cardiovascular-risk populations. The broader weight management discussion — where GLP-1 therapies may still be clinically relevant — is a different, individual conversation.

For GPs reading this: the full consensus statement is worth the time. The PBS access problem will frustrate both patients and clinicians. Being clear about what the evidence supports, what the access situation actually is, and what PBAC timelines look like — that is the foundation for an honest and useful consultation.

This is general information. Cardiovascular risk management is individual — the right approach depends on your full clinical picture, current medications, kidney function, and a range of other factors that an article can flag but cannot assess. The specific clinical decision belongs in the consult.

---

Verdict

Verdict: yes — worth knowing about.

Australia’s first formal obesity-CVD consensus statement is a landmark document: it formally positions weight as a treatable cardiovascular risk factor, anchors its recommendations in SELECT-level RCT evidence, names specific medicines with proven cardiovascular benefit, and explicitly confronts the weight stigma that has historically made this conversation harder to have in consulting rooms. The access gap remains real. But if you have established cardiovascular disease and haven’t yet had this conversation with your GP, this statement gives you and your doctor a shared clinical reference point. That’s worth knowing about.

---

Sources cited

1. Obesity and CVD Consensus Statement — Heart Foundation
2. Briefing: Australia’s first obesity-CVD consensus statement — Scimex
3. GLP-1 therapies key to Australia’s new obesity and CVD guide — MJA InSight
4. ‘Critical role’ of GLP-1s addressed in Australian-first obesity consensus — newsGP
5. New obesity medicines recommended to reduce heart disease risk — Heart Foundation